Stocktoria

Viatris Inc VTRS

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1973-02-01 · LEI

Viatris Inc financials (annual)

Revenue
$11.50B $11.95B $17.89B $16.26B $15.43B $14.74B $14.30B 2019202020212022202320242025
Net income
2019202020212022202320242025
Free cash flow
$1.59B $988.8M $2.56B $2.59B $2.52B $1.98B $1.94B 2019202020212022202320242025

Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue$14.3B$14.7B$15.4B$16.3B$17.9B$11.9B$11.5B
Gross profit$5.0B$5.6B$6.4B$6.5B$5.6B$3.8B$3.9B
R&D expense————$751.1M$555.1M$639.9M
SG&A expense$3.8B$4.1B$4.1B$4.2B$4.5B$3.3B$2.6B
Operating income-$2.7B$10.1M$766.2M$1.6B-$34.0M-$210.8M$715.5M
Interest expense$471.3M$550.0M$573.1M$592.4M$636.2M$497.8M$517.3M
Income tax-$150.1M$11.0M$148.2M$734.6M$604.7M-$51.3M$137.6M
Operating cash flow$2.3B$2.3B$2.9B$3.0B$3.0B$1.2B$1.8B
Free cash flow$1.9B$2.0B$2.5B$2.6B$2.6B$988.8M$1.6B
Cash & equivalents$1.3B$734.8M$991.9M$1.3B$701.2M$844.4M$475.6M
Inventory$4.0B$3.9B$3.5B$3.5B$4.0B$5.5B$2.7B
Total assets$37.2B$41.5B$47.7B$50.0B$54.8B$61.6B$31.3B
Total liabilities$22.5B$22.9B$27.2B$28.9B$34.4B$38.6B$19.4B
Shareholders' equity$14.7B$18.6B$20.5B$21.1B$20.5B$23.0B$11.9B
EPS (diluted)$-3.00$-0.53$0.05$1.71$-1.05$-0.49$0.01

Growth · year-over-year · Revenue CAGR 3.7%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue growth-3.0%-4.5%-5.1%-9.1%+49.7%+3.9%—
EPS growth—-1160.0%-97.1%——-3800.0%—
Free cash flow growth-2.0%-21.6%-2.7%+1.3%+158.9%-37.8%—

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.